{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:01:59Z","timestamp":1747180919912,"version":"3.40.5"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>We report a 5-year-old boy who presented with progressive weakness in 4 limbs and gait disorders over 7 months. No skin rash was observed on admission. A symmetrical proximodistal weakness was found. The creatine kinase level was normal with a slightly elevated lactate dehydrogenase level. Biopsy specimens showed infiltration of mononuclear cells, few necrotic fibers, and perifascicular atrophy. Screening for myositis-specific antibodies was positive for the antinuclear matrix protein 2 antibody, which is mainly associated with dermatomyositis. Symptoms improved on receiving corticosteroids. Our findings suggest that in cases where inflammatory muscle disease is suspected, antinuclear matrix protein 2 antibody analyses should be considered for precise diagnosis, even with the absence of dermatological symptoms. The case suggests consideration of juvenile dermatomyositis in children with no associated skin manifestations or elevated creatine kinase levels and highlights the importance of screening for myositis-specific antibodies in helping with the diagnosis, given the possible heterogeneity of its clinical presentations.<\/jats:p>","DOI":"10.1097\/cnd.0000000000000455","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T20:04:05Z","timestamp":1692821045000},"page":"46-50","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Juvenile Dermatomyositis Without Skin Lesions in an Antinuclear Matrix Protein 2 Antibody Seropositive Pediatric Case"],"prefix":"10.1097","volume":"25","author":[{"given":"Fatma","family":"Kamoun","sequence":"first","affiliation":[{"name":"Child Neurology Department, Hedi Chaker Sfax University Hospital, Sfax, Tunisia;"},{"name":"LR19ES15 University of Sfax, Tunisia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4152-8181","authenticated-orcid":false,"given":"Sirine","family":"Laroussi","sequence":"additional","affiliation":[{"name":"Child Neurology Department, Hedi Chaker Sfax University Hospital, Sfax, Tunisia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azza","family":"Mellouli","sequence":"additional","affiliation":[{"name":"Child Neurology Department, Hedi Chaker Sfax University Hospital, Sfax, Tunisia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olfa","family":"Jallouli","sequence":"additional","affiliation":[{"name":"Child Neurology Department, Hedi Chaker Sfax University Hospital, Sfax, Tunisia;"},{"name":"LR19ES15 University of Sfax, Tunisia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sawsan","family":"Feki","sequence":"additional","affiliation":[{"name":"Autoimmunity, Cancer and Immunogenetics Research Laboratory (LR18SP12), Immunology Department, Habib Bourguiba University Hospital, Sfax, Tunisia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samia","family":"Ben Sassi","sequence":"additional","affiliation":[{"name":"Neurology Department, National Institute of Neurology, Tunis, Tunisia; and"},{"name":"Faculty of Medicine of Tunis, Neurosciences Department, University of Tunis El Manar, Tunis, Tunisia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chahnez","family":"Charfi Triki","sequence":"additional","affiliation":[{"name":"Child Neurology Department, Hedi Chaker Sfax University Hospital, Sfax, Tunisia;"},{"name":"LR19ES15 University of Sfax, Tunisia;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250507","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11926-019-0871-4","article-title":"Juvenile dermatomyositis\u2014clinical phenotypes","volume":"21","author":"Li","year":"2019","journal-title":"Curr Rheumatol Rep"},{"key":"R2-20250507","first-page":"269","article-title":"Polymyositis and dermatomyositis","volume":"12","author":"PEARSON","year":"1962","journal-title":"Bull Rheum Dis"},{"key":"R3-20250507","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","article-title":"A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups","volume":"70","author":"Love","year":"1991","journal-title":"Medicine"},{"key":"R4-20250507","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"key":"R5-20250507","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.rdc.2013.06.001","article-title":"Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies","volume":"39","author":"Rider","year":"2013","journal-title":"Rheum Dis Clin North Am"},{"key":"R6-20250507","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.nmd.2018.06.011","article-title":"Juvenile dermatomyositis forty years on: case report","volume":"28","author":"Rego de Figueiredo","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"R7-20250507","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","article-title":"Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort","volume":"84","author":"Tansley","year":"2017","journal-title":"J Autoimmun"},{"key":"R8-20250507","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/MD.0b013e31829d08f9","article-title":"The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies","volume":"92","author":"Rider","year":"2013","journal-title":"Medicine"},{"key":"R9-20250507","first-page":"98","article-title":"Clinical differences between adult and juvenile dermatomyositis associated with anti-NXP2 autoantibodies","volume":"64","author":"Tansley","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R10-20250507","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"R11-20250507","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/rheumatology\/keab518","article-title":"Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash","volume":"61","author":"Ichimura","year":"2022","journal-title":"Rheumatology"},{"key":"R12-20250507","doi-asserted-by":"crossref","first-page":"1","DOI":"10.23937\/2469-5726\/1510025","article-title":"In the idiopathic inflammatory myopathies, how significant is creatine kinase levels in diagnosis and prognosis? A case study and review of the literature","volume":"1","author":"Sizemore","year":"2015","journal-title":"J Rheum Dis Treat"},{"key":"R13-20250507","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/acr.23210","article-title":"Cutaneous and systemic findings associated with nuclear matrix protein 2 antibodies in adult dermatomyositis patients","volume":"69","author":"Rogers","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R14-20250507","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1002\/art.23960","article-title":"Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features","volume":"58","author":"Stringer","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R15-20250507","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R17-20250507","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12016-015-8512-9","article-title":"Idiopathic inflammatory myopathies: an update on classification and treatment with special focus on juvenile forms","volume":"52","author":"Pagnini","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"R18-20250507","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fneur.2016.00064","article-title":"Idiopathic inflammatory myopathies: clinical approach and management","volume":"7","author":"Malik","year":"2016","journal-title":"Front Neurol"},{"key":"R19-20250507","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/acr.20695","article-title":"Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference","volume":"64","author":"Huber","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R20-20250507","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40674-018-0106-2","article-title":"Current treatment for myositis","volume":"4","author":"Barsotti","year":"2018","journal-title":"Curr Treat Options Rheumatol"},{"key":"R21-20250507","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.pcl.2018.04.006","article-title":"Juvenile idiopathic inflammatory myopathies","volume":"65","author":"Huber","year":"2018","journal-title":"Pediatr Clin North Am"},{"key":"R22-20250507","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s10067-020-05291-1","article-title":"Assessment of diagnostic utility, clinical phenotypic associations, and prognostic significance of anti-NXP2 autoantibody in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis","volume":"40","author":"Li","year":"2021","journal-title":"Clin Rheumatol"}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000455","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T21:03:43Z","timestamp":1746651823000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0000000000000455","relation":{},"ISSN":["1522-0443"],"issn-type":[{"type":"print","value":"1522-0443"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}